Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes by Frank J. Borm, Jasper Smit, Joyce Bakker, Maurits Wondergem, Egbert F. Smit, Adrianus J. de Langen, Tanja D. de Gruijl

Get full text

Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study by Egbert F Smit, Willemijn S M E Theelen, Michiel M Smeenk, Vincent van der Noort, Jeroen M A Hendrikx, Hanieh Abedian Kalkhoran

Get full text

MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy by Michael Thomas, Petros Christopoulos, Wade T Iams, Julien Mazieres, Alexis B Cortot, Nir Peled, Gabriele Minuti, Egbert F Smit, Francois Audhuy, Karin Berghoff, S Peter Eggleton, Frank Fries, Maike Hildenbrand, Peter Liu, Seyed Hamidreza Mahmoudpour, Christoph Menzel, Dina Oksen

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products by Suzanne M. Castenmiller, Nandhini Kanagasabesan, Aurélie Guislain, Benoît P. Nicolet, Marleen M. van Loenen, Kim Monkhorst, Alexander A.F.A. Veenhof, Egbert F. Smit, Koen J. Hartemink, John B.A.G. Haanen, Rosa de Groot, Monika C. Wolkers

Get full text